Glucagon-like peptide-1 (GLP-1) receptor agonists in type 2 diabetes and long-term complications: FOCUS on retinopathy

L Marchand; C Luyton; A Bernard

doi:10.1111/dme.14390

Glucagon-like peptide-1 (GLP-1) receptor agonists in type 2 diabetes and long-term complications: FOCUS on retinopathy

Diabet Med. 2021 Jan;38(1):e14390. doi: 10.1111/dme.14390. Epub 2020 Sep 27.

Authors

L Marchand¹, C Luyton¹, A Bernard^{2

3}

Affiliations

¹ Department of Endocrinology and Diabetes, Centre Hospitalier Saint Joseph Saint Luc, Lyon.
² Department of Ophthalmology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre-Bénite.
³ Department of Ophthalmology, Centre Hospitalier Saint Joseph Saint Luc, Lyon, France.

PMID: 32799379
DOI: 10.1111/dme.14390

No abstract available

Keywords: ACCORD; ADVANCE; Diabetic Retinopathy; ELIXA; EXSCEL; Eye events; FOCUS; GLP-1; Glucagon-like peptide-1 receptor agonists; HARMONY Outcomes; LEADER; Liraglutide; Lixisenatide; Long-term complications; Microvascular complications; PIONEER-6; REWIND; SUSTAIN-6; Semaglutide; Type 2 Diabetes; UKPDS; VADT; albiglutide; dulaglutide; exenatide; oral semaglutide.

MeSH terms

Diabetes Mellitus, Type 2 / complications*
Diabetes Mellitus, Type 2 / drug therapy*
Diabetic Retinopathy / epidemiology*
Glucagon-Like Peptide-1 Receptor / agonists*
Humans
Hypoglycemic Agents / therapeutic use*
Randomized Controlled Trials as Topic

Substances

Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents